



**COPY OF ALL CLAIMS**

1. A method for the treatment of co-morbid conditions associated with obesity in a human in need of such treatment which comprises administration to the human of a therapeutically effective amount of a compound of formula I




including enantiomers and pharmaceutically acceptable salts thereof, in which  $\text{R}_1$  and  $\text{R}_2$  are independently H or methyl, and a therapeutically effective amount of a compound of formula II




- wherein the compound of formula I and the compound of formula II are administered simultaneously, separately or sequentially.
2. A method according to claim 1 in which the compound of formula I is N-{1-[1-(4-chlorophenyl)cyclobutyl]-e-methylbutyl}-N,N-dimethylamine or a salt thereof.
3. A method according to claim 2 wherein the compound of formula I is administered 30 minutes to 3 hours prior to the administration of the compound of formula II.

4. (amended) A compound of formula I as defined in claim 1 including enantiomers and pharmaceutically acceptable salts thereof, in which  $R_1$  and  $R_2$  are independently H or methyl and the compound of formula II as defined in claim 1 for simultaneous, separate or sequential use for the treatment of co-morbid conditions associated with obesity.
5. (amended) A compound of formula I as defined in claim 1 including enantiomers and pharmaceutically acceptable salts thereof, in which  $R_1$  and  $R_2$  are independently H or methyl and the compound of formula II as defined in claim 1 as a combined preparation for simultaneous, separate or sequential use for the treatment of co-morbid conditions associated with obesity.
6. (amended) A product containing a compound of formula I as defined in claim 1 including enantiomers and pharmaceutically acceptable salts thereof, in which  $R_1$  and  $R_2$  are independently H or methyl and the compound of formula II as defined in claim 1 as combined preparation for simultaneous, separate, or sequential use for the treatment of co-morbid conditions associated with obesity,
7. (amended) A process of manufacturing a medicament for the treatment of co-morbid conditions associated with obesity in a patient who is also receiving treatment with orlistat comprising the step of incorporating into said medicament an effective amount of a compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which  $R_1$  and  $R_2$  are independently H or methyl.
8. A pharmaceutical composition comprising a compound of formula I



including enantiomers and pharmaceutically acceptable salts thereof, in which R<sub>1</sub> and R<sub>2</sub> are independently H or methyl, and the compound of formula II



in conjunction with a pharmaceutically acceptable diluent or carrier.